Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endoscopy-driven vs systematic biologic therapy after ileocolonic resection in Crohn’s disease
2022-500311-39-00Phase 4Authorised
- Sponsor
- UZ Leuven
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 4, randomised trial of adalimumab, infliximab, ustekinumab, vedolizumab, risankizumab and 2 more in Crohn's disease (2 arms), sponsored by UZ Leuven. Planned start Jun 2022; status: authorised.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2022-500311-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500311-39-00.